UB Paderborn / Katalog / Suche / in CDI

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

The lancet oncology, 2023-03, Vol.24 (3), p.228-238

2023

Volltextzugriff (PDF)

Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor–induced inflammatory arthritis

Clinical rheumatology, 2019-05, Vol.38 (5), p.1513-1519

2019

Volltextzugriff (PDF)

Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium

The Journal of urology, 2023-04, Vol.209 (4), p.701-709

2023

Volltextzugriff (PDF)

Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma

European urology, 2020-10, Vol.78 (4), p.615-623

2020

Volltextzugriff (PDF)

Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

European urology, 2024-07, Vol.86 (1), p.4-9

2024

Volltextzugriff (PDF)

Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Cancer, 2018-09, Vol.124 (18), p.3677-3683

2018

Volltextzugriff (PDF)

Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma

European urology, 2023-07, Vol.84 (1), p.109-116

2023

Volltextzugriff (PDF)

A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System

The Journal of urology, 2022-10, Vol.208 (4), p.804-812

2022

Volltextzugriff (PDF)

Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials

European journal of cancer (1990), 2021-07, Vol.151, p.115-125

2021

Volltextzugriff (PDF)

Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial

Journal of thoracic oncology, 2024-06, Vol.19 (6), p.941-953

2024

Volltextzugriff (PDF)

Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

Therapeutic Advances in Medical Oncology, 2022, Vol.14, p.175883592211086-17588359221108685

2022

Volltextzugriff (PDF)

Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens

The oncologist (Dayton, Ohio), 2024-04, Vol.29 (8), p.699-706

2024

Volltextzugriff (PDF)

Rapid atrophy of cardiac left ventricular mass in patients with non‐small cell carcinoma of the lung

Journal of cachexia, sarcopenia and muscle, 2019-10, Vol.10 (5), p.1070-1082

2019

Volltextzugriff (PDF)

2023 American Society of Clinical Oncology (ASCO) Symposium: Meeting highlights

Canadian Urological Association journal, 2023-09, Vol.17 (9), p.E302-7

2023

Volltextzugriff (PDF)

Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors

Canadian Urological Association journal, 2016-11, Vol.10 (11-12Suppl7), p.S242-S244

Basappa, Naveen S

2016

Volltextzugriff (PDF)

The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial

European journal of cancer (1990), 2019-02, Vol.108, p.69-77

2019

Volltextzugriff (PDF)

2022 American Society of Clinical Oncology (ASCO): Meeting highlights

Canadian Urological Association journal, 2022-09, Vol.16 (9), p.E499-504

2022

Volltextzugriff (PDF)

Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience

Urologic oncology, 2020-10, Vol.38 (10), p.799.e1-799.e10

2020

Volltextzugriff (PDF)

Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population

Urologic oncology, 2023-07, Vol.41 (7), p.328.e15-328.e23

2023

Volltextzugriff (PDF)

Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis)

Clinical genitourinary cancer, 2024-06, Vol.22 (3), p.102060-102060, Article 102060

2024

Volltextzugriff (PDF)

Setting Research Priorities for Kidney Cancer

European urology, 2017-12, Vol.72 (6), p.861-864

2017

Volltextzugriff (PDF)

Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada

Prostate cancer and prostatic diseases, 2023-03, Vol.26 (1), p.74-79

2023

Volltextzugriff (PDF)

Undiagnosed cardiac deficits in non-small cell carcinoma patients in the candidate population for anti-cachexia clinical trials

Supportive care in cancer, 2019-04, Vol.27 (4), p.1551-1561

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor–induced inflammatory arthritis

Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium

Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma

Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma

A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System

Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials

Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial

Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens

Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Rapid atrophy of cardiac left ventricular mass in patients with non‐small cell carcinoma of the lung

2023 American Society of Clinical Oncology (ASCO) Symposium: Meeting highlights

Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors

The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial

2022 American Society of Clinical Oncology (ASCO): Meeting highlights

Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience

Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population

Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis)

Setting Research Priorities for Kidney Cancer

Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada

Undiagnosed cardiac deficits in non-small cell carcinoma patients in the candidate population for anti-cachexia clinical trials

Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada

Suchergebnisse filtern